elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34499662-33CDB3CC-B748-4424-B782-779FB71B7453
Q34499662-33CDB3CC-B748-4424-B782-779FB71B7453
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34499662-33CDB3CC-B748-4424-B782-779FB71B7453
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
P921
Q34499662-33CDB3CC-B748-4424-B782-779FB71B7453
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34499662-33CDB3CC-B748-4424-B782-779FB71B7453
rank
NormalRank
type
BestRank
Statement
P921
patient